Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | TK2 | O00142 | 5/20 | 0.50 |
| ▸ | TK1 | P04183 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8301264 | 0.89 | TYMP (0.56) | TYMPMAPK1HPGDTK2TK1 | |
| SCHEMBL26034750 | 0.86 | TK2 (0.56) | TYMPMAPK1HPGDTK2TK1 | |
| SCHEMBL15110503 | 0.85 | TK2 (0.60) | TYMPMAPK1HPGDTK2TK1 | |
| SCHEMBL26034737 | 0.85 | MAPK1 (0.59) | TYMPMAPK1HPGDTK1 | |
| SCHEMBL4118603 | 0.83 | MAPK1 (0.57) | TYMPMAPK1HPGDTK2TK1 | |
| SCHEMBL22193320 | 0.82 | TYMP (0.60) | TYMPMAPK1HPGDTK2TK1 | |
| SCHEMBL4083768 | 0.82 | TYMP (0.52) | TYMPMAPK1HPGDTK2TK1 | |
| SCHEMBL4261186 | 0.81 | MAPK1 (0.56) | TYMPMAPK1HPGDTK2TK1 | |
| SCHEMBL5017275 | 0.81 | MAPK1 (0.56) | TYMPMAPK1HPGDTK2TK1 | |
| SCHEMBL4194710 | 0.81 | MAPK1 (0.56) | TYMPMAPK1HPGDTK2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117716032-A | Target gene iRNA compositions related to metabolic disorders and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2024-03-15 | — | — | CN | claimed |
| CN-117377761-A | Compositions and methods for site-specific modification | 阿斯利康(瑞典)有限公司 | 2024-01-09 | — | — | CN | claimed |
| CN-117120610-A | Superoxide dismutase 1 (SOD 1) iRNA compositions for treating or preventing superoxide dismutase 1 (SOD 1) -related neurodegenerative diseases and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-117025791-A | Composition for detecting food meat origin, kit containing same and application | 山西医科大学 | 2023-11-10 | — | — | CN | claimed |
| CN-118119707-A | Use of inhibitors to increase CRISPR/Cas insertion efficiency | 阿斯利康(瑞典)有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117867008-A | Methods and compositions for improving the efficiency of targeted gene modification using oligonucleotide-mediated gene repair | 希博斯美国有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117716032-A | Target gene iRNA compositions related to metabolic disorders and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117377761-A | Compositions and methods for site-specific modification | 阿斯利康(瑞典)有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-117203336-A | Huntingtin (HTT) iRNA pharmaceutical compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-117120610-A | Superoxide dismutase 1 (SOD 1) iRNA compositions for treating or preventing superoxide dismutase 1 (SOD 1) -related neurodegenerative diseases and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117089628-A | Composition and kit for species and human sex identification and application thereof | 山西医科大学 | 2023-11-21 | — | — | CN | disclosed |
| CN-117025791-A | Composition for detecting food meat origin, kit containing same and application | 山西医科大学 | 2023-11-10 | — | — | CN | disclosed |
| US-20210163541-A1 | Method for Preparing PNA Oligomer | SEASUNBIO MATERIALS (KR) | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163541-A1 | Method for Preparing PNA Oligomer | NCL, NOD1, POLI | TYMP 562/4885MAPK1 4492/4885HPGD 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.